• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC IRELAND VENA SEAL CLOSURE SYSTEM; AGENT, OCCLUDING, VASCULAR, PERMANENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC IRELAND VENA SEAL CLOSURE SYSTEM; AGENT, OCCLUDING, VASCULAR, PERMANENT Back to Search Results
Device Problem Biocompatibility (2886)
Patient Problems Erythema (1840); Hypersensitivity/Allergic reaction (1907); Itching Sensation (1943); Local Reaction (2035); Swelling/ Edema (4577); Peripheral Edema (4578)
Event Date 01/01/2021
Event Type  Injury  
Manufacturer Narrative
Incidence and clinical impacts of cynoacrylate induced soft tissue allergic reaction among patients who underwent venaseal procedure.Annals of vascular diseases 2021:14(89).Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
 
Event Description
Cyanoacrylate glue adhesion (ca) is the latest endovenous surgery for chronic venous disease.However, published studies on type iv hypersensitivity after ca showed heterogeneous results in incidence, duration, skin manifestation, and risk factors.From mar 2019 to december 2020, 293 patients who underwent ca procedure were evaluated.Type iv hypersensitivity was identified in 101 cases presented with itching, erythma, painful swelling, heating sense, perivascular edema, and pigmentation.Beyond the local response, systemic manifestation was identified in 18 patients of caistar developed within 3 weeks and last up to 2 weeks.Severe caistar, defined as lasting longer than 3 weeks and combined systemic extension, was noted in 40% of total ca procedure.Caistar was not affect to 1 month and 3 months post operative satisfaction score ranges.When it was compensated for sex, age, bmi and procedure lesion, the multi-variated analysis showed male sex and below the knee lesion procedure were major risk factors of caistar development.Peri-operative steroid injection did not reduce the incidence of caistar, but delayed the onset time and also might reduce the duration, itching sense and severity.Caistar is not an uncommon complication, with an incidence of 34% after the ca procedure.Natures are similar with type iv allergic response and generally benign course.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
VENA SEAL CLOSURE SYSTEM
Type of Device
AGENT, OCCLUDING, VASCULAR, PERMANENT
Manufacturer (Section D)
MEDTRONIC IRELAND
parkmore business park west
galway
EI 
Manufacturer (Section G)
MEDTRONIC IRELAND
parkmore business park west
galway
EI  
Manufacturer Contact
alison sweeney
parkmore business park west
galway 
EI  
091708096
MDR Report Key14975529
MDR Text Key295602277
Report Number9612164-2022-02587
Device Sequence Number1
Product Code PJQ
Combination Product (y/n)N
Reporter Country CodeKS
PMA/PMN Number
P140018
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Literature,Company Representative
Reporter Occupation Physician
Type of Report Initial
Report Date 07/11/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received07/11/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received06/27/2022
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Age61 YR
Patient SexMale
-
-